Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-TCR Summit Europe 2021 | Investigating allogeneic iNKT cell therapy

Marc van Dijk, PhD, Agenus, Cambridge, UK, describes INTELLIGENT invariant natural killer T (iNKT) cell technology, which are innate T-cells with natural killer (NK) cell properties, thus giving them the capacity to hone to diseased tissue sites and recruit components of the immune system to fight disease. This off-the-shelf, allogeneic cell therapy is currently being investigated in clinical trials for hematological malignancies such as multiple myeloma (NCT04754100), as well as acute respiratory syndrome in COVID-19 (NCT04582201). Preclinical research has also indicated the ability of iNKT cells to penetrate tissues and therefore their potential for targeting solid tumors, which could be combined with immune checkpoint antibodies in clinical studies in the future. This interview took place during the CAR-TCR Summit Europe 2021.